MedTrace Logo

Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure

NCT01961726 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2014-10-23

No results posted yet for this study

Summary

A phase I/II study to evaluate the safety and efficacy of JVS-100 administered by retrograde delivery to cohorts of adults with Ischemic Heart Failure.

Conditions

  • Ischemic Heart Failure

Interventions

BIOLOGICAL

Placebo

Coronary Sinus Delivery

BIOLOGICAL

30 mg dose of JVS-100

Coronary Sinus Delivery

BIOLOGICAL

45 mg dose of JVS-100

Coronary Sinus Delivery

Sponsors & Collaborators

  • Juventas Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01961726 on ClinicalTrials.gov